Variations in the sequencing of TERT gene influence risk of breast, ovarian cancers

A major international study involving a Simon Fraser University scientist has found that sequence differences in a gene crucial to the maintenance of our chromosomes' integrity predispose us to certain cancers.

Angela Brooks-Wilson, an associate professor in SFU's biomedical physiology and kinesiology department and a Distinguished Scientist at the BC Cancer Agency, is one of more than 600 scientists globally who contributed to this study.

Published in the March 27, 2013 online issue of the science journal Nature Genetics, the study is called Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer.

The study found that variations in the sequencing of the TERT gene, which encodes an enzyme crucial to telomere maintenance, influence telomere length and our risk of getting breast and ovarian cancers.

Telomeres are structures that encapsulate our chromosomes' ends and are often compared to the plastic protectors on the ends of shoelaces.

These protective structures shorten in length over our lifespan and chromosomal cells should stop dividing when they become too short.

Scientists have known for a while that if chromosomal ends become exposed this can lead to genetic damage and cancer. They've also estimated that up to 80 per cent of telomere-length variation is inherited.

This is the first study to connect that inheritance to predisposition to breast and ovarian cancer.

"This discovery helps us better understand the biology that underlies these cancers, as well as better predict who is likely to develop them," says Brooks-Wilson.

The SFU researcher is one of four investigators in the Ovarian Cancer in Alberta and British Columbia study (OVAL-BC). The interprovincial ovarian cancer study contributed samples and data to this new international study.

"About 140 individual smaller studies like OVAL-BC contributed samples from more than 150,000 women, data and analysis to make this new study happen. It's a remarkable example of international collaboration. I would say this is big science at its collegial best."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
CRISPR-based therapy shown to be safe, effective for people with transthyretin amyloidosis